Krystal Biotech, Inc. (KRYS): Price and Financial Metrics

Krystal Biotech, Inc. (KRYS): $111.33

0.63 (-0.56%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add KRYS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#114 of 357

in industry

KRYS Price/Volume Stats

Current price $111.33 52-week high $133.60
Prev. close $111.96 52-week low $70.51
Day low $109.57 Volume 521,400
Day high $113.33 Avg. volume 297,443
50-day MA $118.90 Dividend yield N/A
200-day MA $116.38 Market Cap 3.14B

KRYS Stock Price Chart Interactive Chart >


Krystal Biotech, Inc. (KRYS) Company Bio


Krystal Biotech Inc. develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The company’s lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. The company was founded in 2015 and is based in Pittsburgh, Pennsylvania.


KRYS Latest News Stream


Event/Time News Detail
Loading, please wait...

KRYS Latest Social Stream


Loading social stream, please wait...

View Full KRYS Social Stream

Latest KRYS News From Around the Web

Below are the latest news stories about KRYSTAL BIOTECH INC that investors may wish to consider to help them evaluate KRYS as an investment opportunity.

Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the Upgrade

Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 20, 2023

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to beremagene geperpavec-svdt (B-VEC or VYJUVEK) for the treatment of dystrophic epidermolysis bullosa (DEB).

Yahoo | December 19, 2023

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […]

Yahoo | December 10, 2023

Here’s Why TimesSquare Capital Management U.S. Small Cap Growth Strategy Added Krystal Biotech (KRYS)

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here. In the quarter the fund returned -3.67% (net), compared to -7.32% return for the Russell 2000 Growth Index. Year-to-date the fund returned 11.56% (net) compared to 9.59% return for […]

Yahoo | December 7, 2023

Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?

The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 5, 2023

Read More 'KRYS' Stories Here

KRYS Price Returns

1-mo -4.05%
3-mo 10.60%
6-mo -11.42%
1-year 41.89%
3-year 41.14%
5-year 387.11%
YTD -10.26%
2023 56.60%
2022 13.25%
2021 16.58%
2020 8.34%
2019 166.51%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!